Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Docetaxel

FDA-approved product (injectable, injection), marketed as Beizray, Docefrez, Docetaxel and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Docetaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • Gastroesophageal junction adenocarcinoma
  • Head and neck carcinoma
  • Head and neck malignant neoplasia
  • Head and neck neoplasia
  • Head and neck squamous cell carcinoma
  • Malignant tumor of neck
  • Metastatic prostate cancer
  • Neoplasm
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Docetaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Docetaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    NCT03839823 · start 2019-02-25

    Registered record
    Registry ID
    NCT03839823
    Conditions
    Breast Cancer
    Interventions
    Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2023-05-10
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib +2 more
    PhasePhase 2
    Registry statusCompleted

  • ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

    NCT04172259 · start 2019-01-10

    Registered record
    Registry ID
    NCT04172259
    Conditions
    Breast Cancer; Neoadjuvant Chemotherapy
    Interventions
    Doxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel; Epirubicin; Pertuzumab; Paclitaxel; Paclitaxel-albumin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-01-10
    Completion
    2026-09-30
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Neoadjuvant Chemotherapy
    InterventionDoxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

    NCT03647488 · start 2018-12-26

    Registered record
    Registry ID
    NCT03647488
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Capmatinib; Spartalizumab; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-12-26
    Completion
    2020-09-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionCapmatinib; Spartalizumab; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

    NCT03632798 · start 2018-08-01

    Registered record
    Registry ID
    NCT03632798
    Conditions
    Recurrent Ovarian Cancer
    Interventions
    ChemoID assay; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-08-01
    Completion
    2019-06-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Ovarian Cancer
    InterventionChemoID assay; Chemotherapy
    PhasePhase 3
    Registry statusWithdrawn

  • Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma

    NCT03585673 · start 2018-06-01

    Registered record
    Registry ID
    NCT03585673
    Conditions
    Esophagus Squamous Cell Carcinoma (SCC); Metastatic Cancer
    Interventions
    Docetaxel-PM; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-06-01
    Completion
    2021-03-30
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagus Squamous Cell Carcinoma (SCC); Metastatic Cancer
    InterventionDocetaxel-PM; Oxaliplatin
    PhasePhase 2
    Registry statusUnknown

  • A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer

    NCT03547804 · start 2018-05-31

    Registered record
    Registry ID
    NCT03547804
    Conditions
    Small-cell Lung Cancer
    Interventions
    Apatinib; chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-31
    Completion
    2020-09-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer
    InterventionApatinib; chemotherapy
    PhasePhase 2
    Registry statusCompleted

  • Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

    NCT03435250 · start 2018-03-04

    Registered record
    Registry ID
    NCT03435250
    Conditions
    Advanced Solid Tumors; Lymphoma
    Interventions
    AG-270; AG-270; AG-270; docetaxel; nab-paclitaxel; gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-03-04
    Completion
    2023-04-20
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; Lymphoma
    InterventionAG-270; AG-270; AG-270; docetaxel +2 more
    PhasePhase 1
    Registry statusTerminated

  • A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

    NCT03430843 · start 2018-01-26

    Registered record
    Registry ID
    NCT03430843
    Conditions
    Esophageal Squamous Cell Carcinoma (ESCC)
    Interventions
    Tislelizumab; Paclitaxel; Docetaxel; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-26
    Completion
    2022-12-28
    Enrolment
    512

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Squamous Cell Carcinoma (ESCC)
    InterventionTislelizumab; Paclitaxel; Docetaxel; Irinotecan
    PhasePhase 3
    Registry statusCompleted

  • Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

    NCT03580395 · start 2017-06-01

    Registered record
    Registry ID
    NCT03580395
    Conditions
    Breast Cancer
    Interventions
    Apatinib; paclitaxel; cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2017-06-01
    Completion
    2022-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionApatinib; paclitaxel; cisplatin
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

    NCT02766140 · start 2016-06

    Registered record
    Registry ID
    NCT02766140
    Conditions
    Non Squamous Non Small Cell Lung
    Interventions
    SHR1020 plus Docetaxel; Placebo plus Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2016-06
    Completion
    2016-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Squamous Non Small Cell Lung
    InterventionSHR1020 plus Docetaxel; Placebo plus Docetaxel
    PhasePhase 3
    Registry statusTerminated

  • Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

    NCT02326285 · start 2015-11

    Registered record
    Registry ID
    NCT02326285
    Conditions
    Non-squamous Non-small Cell Lung Cancer Stage II; Non-squamous Non-small Cell Lung Cancer Stage IIIA; Non-squamous Non-small Cell Lung Cancer Stage IIIB; Activating EGFR Mutation; NSCLC
    Interventions
    Gefitinib; docetaxel; cisplatin; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2015-11
    Completion
    2018-01
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous Non-small Cell Lung Cancer Stage II; Non-squamous Non-small Cell Lung Cancer Stage IIIA; Non-squamous Non-small Cell Lung Cancer Stage IIIB; Activating EGFR Mutation +1 more
    InterventionGefitinib; docetaxel; cisplatin; Surgery
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer

    NCT02274610 · start 2014-11

    Registered record
    Registry ID
    NCT02274610
    Conditions
    Solid Tumor
    Interventions
    Docetaxel-PNP; Taxotere
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11
    Completion
    2015-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionDocetaxel-PNP; Taxotere
    PhasePhase 1
    Registry statusCompleted

  • Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma

    NCT02402842 · start 2014-09

    Registered record
    Registry ID
    NCT02402842
    Conditions
    Anal Canal Carcinoma
    Interventions
    Docetaxel, Cisplatin and 5-Fluorouracil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2020-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Canal Carcinoma
    InterventionDocetaxel, Cisplatin and 5-Fluorouracil
    PhasePhase 2
    Registry statusCompleted

  • A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

    NCT02522234 · start 2014-02-25

    Registered record
    Registry ID
    NCT02522234
    Conditions
    Neutropenia
    Interventions
    F-627 240 μg/kg; F-627 320 μg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-02-25
    Completion
    2015-08-19
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia
    InterventionF-627 240 μg/kg; F-627 320 μg/kg
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

    NCT01958580 · start 2013-09-17

    Registered record
    Registry ID
    NCT01958580
    Conditions
    Stage IA Uterine Sarcoma; Stage IB Uterine Sarcoma; Stage IC Uterine Sarcoma; Stage IIA Uterine Sarcoma; Stage IIB Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Corpus Leiomyosarcoma
    Interventions
    Gemcitabine Hydrochloride; Docetaxel; Internal Radiation Therapy; Intensity-Modulated Radiation Therapy; External Beam Radiation Therapy; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2013-09-17
    Completion
    2017-02-24
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IA Uterine Sarcoma; Stage IB Uterine Sarcoma; Stage IC Uterine Sarcoma; Stage IIA Uterine Sarcoma +7 more
    InterventionGemcitabine Hydrochloride; Docetaxel; Internal Radiation Therapy; Intensity-Modulated Radiation Therapy +2 more
    PhaseNot applicable
    Registry statusTerminated